Gayathri Kallukaran is a Junior Journalist with Eastern Eye. She has a Master’s degree in Journalism and Mass Communication from St. Paul’s College, Bengaluru, and brings over five years of experience in content creation, including two years in digital journalism. She covers stories across culture, lifestyle, travel, health, and technology, with a creative yet fact-driven approach to reporting. Known for her sensitivity towards human interest narratives, Gayathri’s storytelling often aims to inform, inspire, and empower. Her journey began as a layout designer and reporter for her college’s daily newsletter, where she also contributed short films and editorial features. Since then, she has worked with platforms like FWD Media, Pepper Content, and Petrons.com, where several of her interviews and features have gained spotlight recognition. Fluent in English, Malayalam, Tamil, and Hindi, she writes in English and Malayalam, continuing to explore inclusive, people-focused storytelling in the digital space.
Samaritans plans to close at least half of its 200 branches over the next 7–10 years
Volunteers to be moved into larger regional hubs and remote call handling to be piloted
Charity says model is unsustainable; changes aim to increase volunteer flexibility and service capacity
Some volunteers express concern over the loss of smaller branch camaraderie and safe spaces
Final decision expected in September following consultation
Mental health charity plans shift to larger hubs and remote volunteering
Samaritans has announced plans to close at least 100 of its 201 branches across the UK and Ireland in the next seven to ten years, as part of a major restructuring strategy aimed at improving service delivery and reducing infrastructure costs.
The charity, which operates a 24/7 mental health helpline, says it intends to move volunteers into larger regional centres and trial a remote volunteering model. The shift is intended to provide greater flexibility, increase the number of volunteers on shift at any time, and reduce spending on building maintenance.
Concerns raised over impact on volunteers
Samaritans currently has 22,000 listening volunteers who answer calls and messages from people experiencing mental health crises. The helpline receives a call every 10 seconds, and many branches also offer in-person support.
In a video shared with volunteers, Chief Executive Julie Bentley said the charity’s limited fundraising income was increasingly being used to maintain physical branches, instead of improving services.
“Over 200 branches, varying in size from 10 to 300 volunteers, is not sustainable and hinders us providing the best possible service to people who need us,” she said. “We are engaging with our volunteers on proposed improvements that will mean we are able to answer more calls, have more volunteers on duty, and be there for more people in their darkest moments.”
The charity emphasised that it does not intend to reduce the level of service it offers. Instead, it hopes to expand its reach by making buildings and shifts more accessible and increasing volunteer numbers through flexible models.
Volunteer response: fears of “call centre-style” culture
Despite the stated goals, some long-standing volunteers have raised concerns that the changes could lead to a loss of the close-knit environment offered by smaller branches. There is particular unease about the possible shift to a “call centre-style” approach, which some feel could compromise the sense of community and safety among volunteers.
One volunteer commented:
“The current system has operated very successfully for 70 years. Now they’re thinking of dismantling it. Almost every volunteer I’ve spoken to has said if they introduce call centres, we’re out.”
Others voiced discomfort at the idea of taking sensitive calls from home, even with video support from fellow volunteers, citing the importance of having a safe, supportive physical environment.
Financial pressures and long-term planning
The proposed changes come amid financial challenges for the organisation. In its 2023–24 accounts, Samaritans reported declining income for the third consecutive year and rising operational costs.
The charity’s accounts show:
£7 million allocated to fixed assets, including branches
A property maintenance fund of £28,000
A branch support fund of £287,000
£24.6 million in charitable income
Volunteers have requested more transparency around projected cost savings from branch closures and how these funds will be reinvested.
Consultation ongoing ahead of decision
Samaritans has said that no final decisions will be made until after a consultation period concludes in September. If approved, the changes will be introduced gradually over a number of years.
The charity maintains that modernising the structure is essential for long-term sustainability and to meet the evolving needs of callers and volunteers alike.
Mounjaro (tirzepatide) is a diabetes drug also prescribed for weight loss
Users report emotional side effects, including low motivation and feeling “stuck”
A TikTok post describing the “slow middle” of weight loss struck a chord with others
The injection can support weight loss of up to 20% over a year
Drug is now sold in UK supermarkets including Tesco and Morrisons
While Mounjaro has become increasingly popular for aiding weight loss, users have begun highlighting a less-discussed side effect — an emotional downturn midway through treatment.
The medication, also known by its generic name tirzepatide, is a weekly injection originally developed to manage type 2 diabetes. It has since gained traction for its weight loss benefits, with some patients shedding up to 20% of their body weight over the course of a year.
Now available in UK supermarket pharmacies, including Tesco and Morrisons, Mounjaro is being used more widely — but not all side effects are physical.
TikTok user describes the “slow middle” struggle
Social media has recently drawn attention to the psychological challenges that can emerge partway through treatment. TikTok creator @Swedish_Sandra described feeling emotionally flat and demotivated despite ongoing physical progress.
“It’s the period of time between the before and after photos,” she explained in a recent post. “This phase feels quiet — not the start, not the finish, just the slow middle where everything is shifting but the big change isn’t visible yet.”
Sandra encouraged others to recognise that this emotional plateau is part of the journey, calling it “the hardest bit mentally” and stressing the importance of patience and perseverance.
Users share similar experiences
Sandra’s experience resonated with many who commented on her post, saying they too had noticed a dip in motivation once the initial rapid weight loss slowed.
“I’ve been struggling for the last month wondering if all this money is worth it,” wrote one user. “My weight loss has stalled too,” added another. “It is hard to get used to when you’re used to big drops at the start.”
Several commenters offered support and perspective, with one noting:
“Even a quarter of a pound a week is still a loss. This is the phase where the weight lost is likely fat, not just water. That’s real progress.”
Sandra responded:
“The initial excitement has died down, but those ‘boring’ moments are where the steady, lasting change happens.”
A reminder that weight loss is not linear
While Mounjaro has proven effective for weight loss, the emotional and mental health aspects of the process are increasingly part of the conversation. Users are calling for greater openness around the slower, less visible phases of the journey.
The drug remains a significant tool for people managing obesity or type 2 diabetes, but the growing number of personal accounts highlight the importance of setting realistic expectations and maintaining emotional resilience throughout treatment.
By clicking the 'Subscribe’, you agree to receive our newsletter, marketing communications and industry
partners/sponsors sharing promotional product information via email and print communication from Garavi Gujarat
Publications Ltd and subsidiaries. You have the right to withdraw your consent at any time by clicking the
unsubscribe link in our emails. We will use your email address to personalize our communications and send you
relevant offers. Your data will be stored up to 30 days after unsubscribing.
Contact us at data@amg.biz to see how we manage and store your data.
Many of those targeted missed their vaccine during school years
NHS encourages unvaccinated people aged 16–25 to get the HPV vaccine
Over 418,000 school leavers in past three years missed vaccination
HPV vaccine protects against cervical and other related cancers
NHS aiming for 90% uptake among girls by 2040
Letters, emails, texts and NHS App alerts being used for reminders
NHS campaign targets unvaccinated young adults
The NHS is urging hundreds of thousands of young people aged 16 to 25 to come forward for the HPV vaccine, which protects against cervical and other types of cancer.
Many of those targeted missed their vaccine during school years. According to NHS England, over 418,000 children left school without receiving the HPV jab in the past three years.
As part of a national campaign to increase uptake, GP practices are contacting eligible patients using letters, text messages, emails and the NHS App.
Addressing regional disparities and missed vaccinations
The vaccine is routinely offered to boys and girls aged 12 to 13. However, government data from June 2024 highlighted regional inequalities in vaccine uptake. The lowest rates were reported in London, across both male and female Year 10 pupils during the 2023–2024 school year.
The UK Health Security Agency (UKHSA) and NHS England are now focusing on improving awareness and access for young adults who missed vaccination earlier in life.
HPV vaccine effectiveness and long-term plans
The NHS aims to eliminate cervical cancer by 2040 under its 10-Year Health Plan, which includes boosting vaccine uptake to 90% among girls and increasing participation in cervical screening.
The vaccine also helps prevent cancers of the mouth, throat, anus, penis and vagina caused by the human papillomavirus (HPV).
Introduced in 2021, the latest version of the HPV vaccine is more effective than the previous type. Long-term projections suggest it could reduce cases of women's cancer by 16% and HPV-related deaths by 9%.
Research in England shows that the vaccine prevents 90% of cervical cancer cases.
Catch-up vaccinations available for adults
Catch-up doses are available to:
Anyone up to age 25 who missed their school vaccination
Adults up to age 45 with immune-compromised conditions
Men who have sex with men
Dr Amanda Doyle, National Director for Primary Care and Community Services at NHS England, said: “Too many lives are lost to cervical cancer. The hard work of NHS staff in vaccinating and screening as many people as possible will help us meet our ambition of wiping out this disease.”
Dr Sharif Ismail, Director of Public Health Analysis at UKHSA, added: “Uptake of the HPV vaccination has dropped significantly since the pandemic, leaving thousands at greater risk. We urge all parents to return consent forms promptly, and young adults should speak to their GP about catch-up options. It’s never too late to get protected.”
Keep ReadingShow less
He now believes that commercial interests may be at odds with his philosophical mission
Bryan Johnson, 47, is contemplating shutting down or selling his anti-ageing startup, Blueprint.
The biotech entrepreneur recently launched a religion called "Don’t Die."
He says commercial activity is undermining his philosophical credibility.
Blueprint has faced financial pressures but Johnson denies any crisis.
Biotech entrepreneur and longevity enthusiast Bryan Johnson has revealed he is considering shutting down or selling his anti-ageing company, Blueprint. Speaking to Wired, the 47-year-old said his priorities have shifted towards developing his newly founded religion, "Don’t Die", which he believes better aligns with his philosophical ambitions.
“I am so close to either shutting it down or selling it,” Johnson said in the interview published Monday. “I don’t need the money, and it’s a pain-in-the-ass company.”
From business to belief
Johnson is widely known for Project Blueprint, his intense and expensive self-experimentation regimen aimed at reversing ageing. Launched in 2021, the programme reportedly costs him around $2 million annually and has included controversial practices such as blood transfusions from his son, which he later discontinued due to lack of observable benefits.
Blueprint, his startup, sells wellness products ranging from a £42 mushroom-based coffee alternative called “Super Shrooms” to a £44 “longevity mix” drink.
In March, Johnson publicly declared the founding of his own religion, “Don’t Die”, which evolved from the tagline of his wellness brand and Netflix documentary. “It seemed obvious that they’d say Don’t Die is how humanity saved itself and merged with AI,” he wrote on X.
However, he now believes that commercial interests may be at odds with his philosophical mission. “People see the business and give me less credibility on the philosophy side. I will not make that trade-off,” he told Wired.
Financial pressures and public perception
Earlier this year, The New York Times reported that Blueprint was missing its monthly break-even target by over £780,000 ($1 million), citing internal documents and former employees. Johnson responded to some of the allegations, but notably avoided directly addressing the financial data.
To Wired, he maintained that the company is not in a financial crisis. “We are break-even, and I’ve said that publicly many times. We’ve had profitable months, we’ve had loss months,” he said.
Blueprint originally emerged from requests by friends who were curious about the supplements Johnson was taking. “I was trying to do people a solid,” he said. Yet, the enterprise has grown into something that, he now feels, undermines the authenticity of his philosophical pursuits.
Morrisons Clinic introduces subscription service for tirzepatide injections
The treatment may aid weight loss of up to 20% over one year
Monthly subscription will increase from £129 to £159 after introductory period
Service includes medical assessment and regular check-ins
Criticism emerges over the supermarket’s continued sale of unhealthy food
Morrisons has launched an online subscription service offering weight loss injections, prompting mixed reactions from the public. The supermarket’s online health platform, Morrisons Clinic, now offers tirzepatide — also known by the brand name Mounjaro — for weight management.
Tirzepatide is primarily prescribed to treat type 2 diabetes, but has also been approved for weight loss. According to Morrisons Clinic, users may lose up to 20 per cent of their body weight over the course of a year.
Cost and treatment details
The service is priced at £129 for the first month, increasing to £159 thereafter. Before beginning treatment, customers are required to complete a medical assessment. Monthly check-ins with a clinical team are part of the subscription, and all prescriptions are handled by trained pharmacists.
“Our expert prescribing pharmacists are specially trained to review, consult and provide medications online,” the website states. “Your healthcare journey is in safe hands.”
The clinic describes its services as being “designed with your long-term health as our priority.”
Backlash over perceived mixed messaging
The move has sparked criticism on social media, with some users accusing the chain of hypocrisy. Critics pointed out that while the supermarket offers medical treatment for weight loss, it also continues to sell ultra-processed, high-fat and high-sugar foods.
One user commented: “It’s genius really. The store sells you unhealthy grub that gets you fat, then wants vast sums of money to get you thin.” Another added: “Is this a parody? One of the culprits, pushing highly processed food, is offering a fat clinic?!”
Morrisons defends online clinic
In response, Morrisons has defended the initiative, stating that its weight loss services are “prescribed and dispensed responsibly.” The clinic offers a range of other health services, including treatments for:
Premature ejaculation (£26.99)
Acne (£36.99)
Acid reflux (£17.99)
Erectile dysfunction (£13)
Migraines (£15.99)
Keep ReadingShow less
NHS England says premature babies are three times more likely to be hospitalised due to RSV
NHS to offer nirsevimab injection to 9,000 premature and high-risk babies from late September
Aims to protect against respiratory syncytial virus (RSV), which can cause severe illness in infants
Premature babies are 10 times more likely to need intensive care for RSV
Nirsevimab offers immediate protection and lasts for six months
Neo-natal units across the UK will deliver the jab
Thousands of premature and high-risk babies in the UK will soon be offered a new immunisation to protect against RSV (respiratory syncytial virus), a common winter virus that can cause serious lung infections and hospitalisation. The NHS will begin delivering the nirsevimab injection from late September, aiming to shield vulnerable infants before the colder months set in.
Premature infants at higher risk from RSV
RSV typically causes coughs and colds, but in some children — particularly those born prematurely or with underlying health conditions — it can lead to bronchiolitis, pneumonia, and breathing difficulties. NHS England says premature babies are three times more likely to be hospitalised due to RSV and ten times more likely to require intensive care compared to full-term infants.
Each year, around 30,000 children under five are admitted to hospital in the UK with RSV, and approximately 30 of them die from complications related to the virus.
New immunisation to deliver immediate protection
While most full-term babies receive protection through maternal vaccination during late pregnancy, those born before 32 weeks miss the opportunity to build sufficient immunity. These infants will now be offered nirsevimab, a long-acting antibody that provides immediate protection for six months in just one dose.
Unlike traditional vaccines that take time to activate the body’s immune response, nirsevimab delivers ready-made antibodies, offering instant defence against infection.
NHS clinics to deliver jabs across the UK
Neo-natal clinics throughout England, Scotland, Wales, and Northern Ireland will administer the injection. Families of vulnerable infants — including those with heart or lung conditions or weakened immune systems — will be advised on how to access the immunisation by their healthcare teams.
Dr Claire Fuller, co-national medical director for NHS England, said the immunisation “will offer a long-lasting defence, helping to avoid unnecessary hospitalisations and serious illness, giving babies the best possible start in life and shielding them from harm.”
Clinical trial success and personal testimony
Ceri Cox, a 33-year-old paediatric nurse, enrolled her two-year-old son Harry in an international clinical trial for nirsevimab at University Hospital Southampton. Having seen the effects of RSV firsthand, she described the rollout as “amazing” and hopes it will help reduce the number of young patients in hospital this winter.
Background on RSV and current vaccination efforts
In 2023, the UK introduced a maternal vaccination programme offering the RSV jab Abrysvo to pregnant women from 28 weeks and to adults aged 75 to 79. The vaccine boosts the mother’s immune system, passing protection to the baby during the first few weeks of life. However, this method is not viable for premature births, hence the need for nirsevimab.
RSV symptoms to watch for
RSV symptoms typically appear a few days after infection and include:
Runny or blocked nose
Cough
Sneezing
Fever or chills
Tiredness
Infants may also show:
Feeding difficulties
Irritability
Wheezing
Rapid or irregular breathing
Loss of appetite
Severe cases can escalate to pneumonia or bronchiolitis, particularly in high-risk infants.